IBT Insider Trading

Insider Ownership Percentage: 4.18%
Insider Buying (Last 12 Months): £82,112.19
Insider Selling (Last 12 Months): GBX 0

International Biotechnology Insider Trading History Chart

This chart shows the insider buying and selling history at International Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

International Biotechnology Share Price & Price History

Current Price: GBX 611
Price Change: Price Decrease of -10 (-1.61%)
As of 06/12/2025 12:47 PM ET

This chart shows the closing price history over time for IBT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

International Biotechnology Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/13/2025Katherine Cornish-BowdenInsiderBuy2,000GBX 585£11,700
2/19/2025Alexa HendersonInsiderBuy6,996GBX 711£49,741.56
12/17/2024Katherine Cornish-BowdenInsiderBuy1,500GBX 713£10,695
7/24/2024Gillian ElcockInsiderBuy1,407GBX 709£9,975.63
11/7/2023Caroline GulliverInsiderBuy2,500GBX 573£14,325
8/3/2023Katherine Cornish-BowdenInsiderBuy1,500GBX 633£9,495
See Full Table

SEC Filings (Institutional Ownership Changes) for International Biotechnology (LON:IBT)

45.21% of International Biotechnology stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

International Biotechnology logo
The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology. Investments may also be made in related sectors such as medical devices and healthcare services. While the Company’s portfolio is held as one pool of assets, for operational purposes there is a quoted portfolio and an unquoted portfolio. The portfolio is diversified by geography, industry sub-sector and investment size with no single investment in a company normally accounting for more than 15% of the portfolio at the time of investment. The portfolio is split between large, mid and small-capitalisation companies, primarily quoted on stock exchanges in North America, where the most established and commercial biotech and other life sciences companies and companies operating in related sectors are based, though investments will also be made in Europe, Asia and Australia. Investments may also be made into unquoted companies and into funds not quoted on a stock exchange, including venture capital funds. This may include funds managed by the Investment Manager and/or members of its group. The primary purpose of investment in unquoted funds will be to gain exposure to unquoted companies. The Company may invest through equities, index-linked securities and debt securities, cash deposits, money market instruments and foreign currency exchange transactions. Forward or derivative transactions are not used by the Company. The Company may borrow from time to time to exploit specific investment opportunities, rather than to apply long-term structural gearing to the Company’s portfolio of investments.
Read More on International Biotechnology

Today's Range

Now: GBX 611
Low: 608
High: 616

50 Day Range

MA: GBX 570.01
Low: 480
High: 632

52 Week Range

Now: GBX 611
Low: 480
High: 736

Volume

45,694 shs

Average Volume

83,526 shs

Market Capitalization

£219.48 million

P/E Ratio

5.83

Dividend Yield

4.20%

Beta

0.21

Who are the company insiders with the largest holdings of International Biotechnology?

International Biotechnology's top insider shareholders include:
  1. Alexa Henderson (Insider)
  2. Caroline Gulliver (Insider)
  3. Gillian Elcock (Insider)
  4. Katherine Cornish-Bowden (Insider)
Learn More about top insider investors at International Biotechnology.